Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma.

Autor: Fang C, Zhu DX, Dong HJ, Zhou ZJ, Wang YH, Liu L, Fan L, Miao KR, Liu P, Xu W, Li JY

Publikováno v: Annals of Hematology; Apr2012, Vol. 91 Issue 4, p553-559, 7p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

[Philadelphia chromosome positive acute lymphoblastic leukemia blast crisis from primary myelofibrosis: a case report].

Autor: Liu YP; The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China., Li F; The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China., Zhu H; The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China., Li JY; The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China., Miao KR; The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.

Publikováno v: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi [Zhonghua Xue Ye Xue Za Zhi] 2023 Jul 14; Vol. 44 (7), pp. 560.

[Clinical analysis of 20 cases of small B lymphocyte proliferative disease with t (14;19) (q32;q13)].

Autor: Yang H; Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China., Guo R; Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China., Shi Y; Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China., Qiao C; Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China., Wu YJ; Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China., Fan L; Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China., Xu W; Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China., Miao KR; Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China., Li JY; Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China., Qiu HR; Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.

Publikováno v: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi [Zhonghua Xue Ye Xue Za Zhi] 2022 Aug 14; Vol. 43 (8), pp. 674-679.

The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Autor: Zou YX; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing Medical University, Nanjing, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China., Zhu HY; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing Medical University, Nanjing, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China., Li XT; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing Medical University, Nanjing, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China., Xia Y; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing Medical University, Nanjing, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China., Miao KR; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing Medical University, Nanjing, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China., Zhao SS; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing Medical University, Nanjing, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China., Wu YJ; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing Medical University, Nanjing, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China., Wang L; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing Medical University, Nanjing, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China., Xu W; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing Medical University, Nanjing, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China., Li JY; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.; Key Laboratory of Hematology of Nanjing Medical University, Nanjing Medical University, Nanjing, China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.

Publikováno v: Hematological oncology [Hematol Oncol] 2019 Oct; Vol. 37 (4), pp. 392-400. Date of Electronic Publication: 2019 Sep 13.